Instead of presenting two distinct technologies, AAVantgarde frames its DNA and protein splicing methods as "two different flanges" of a single platform. This strategic framing emphasizes their core capability—enabling oversized genes—while allowing them to pragmatically choose the most efficient method for each disease target.
Despite an existing academic natural history study (Procstar) for Stargardt disease, AAVantgarde invested in running its own. This gave them a more rigorous and consistent dataset, collected with modern instruments over a shorter period, highlighting the strategic value of controlling baseline data for future pivotal trials.
AAVantgarde's focus on the eye provides a significant manufacturing (CMC) advantage. The small quantities needed for ocular delivery reduce the pressures of scale-up, a common failure point for systemic gene therapies. This allows the team to focus on quality over quantity, contributing to a perfect manufacturing record of zero failed batches.
AAVantgarde learned from its Usher syndrome trial that capturing patient-reported outcomes is essential, especially when traditional functional endpoints like eye charts are slow to change. This strategy ensures they capture meaningful data on patient quality of life, which can be crucial for demonstrating therapeutic benefit in slowly progressing diseases.
AAVantgarde's foundational science originated from the Italian charity Teleton. This provided decades of grant-funded research and de-risked technology, showcasing a powerful, non-traditional model for biotech incubation outside of typical VC or academic spin-out routes, culminating in Teleton achieving the first-ever BLA approval for a charity.